4.7 Article

Acute Ischemic Stroke in Patients With COVID-19 An Analysis From Get With The Guidelines-Stroke

期刊

STROKE
卷 52, 期 5, 页码 1826-1829

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.121.034301

关键词

coronavirus; COVID-19; hospital; ischemic stroke; mortality

资金

  1. Genentech, Inc-A Member of the Roche Group
  2. Novartis
  3. Boehringer Ingelheim
  4. Eli Lilly Diabetes Alliance
  5. Novo Nordisk
  6. Sanofi
  7. AstraZeneca
  8. Bayer
  9. Portola Pharmaceuticals

向作者/读者索取更多资源

Patients with AIS and COVID-19 had younger age, greater stroke severity, longer evaluation and treatment times, decreased odds of discharge with modified Rankin Scale score of <= 2, and increased odds of in-hospital mortality compared with those with AIS and no COVID-19.
Background and Purpose: Studies suggest an increased risk of adverse outcomes among patients with acute ischemic stroke (AIS) and coronavirus disease 2019 (COVID-19). Methods: Using Get With The Guidelines-Stroke, we identified 41 971 patients (AIS/COVID-19: 1143; AIS/no COVID-19: 40 828) with AIS hospitalized between February 4, 2020 and June 29, 2020, from 458 Get With The Guidelines-Stroke hospitals with at least one COVID-19 case and evaluated clinical characteristics, treatment patterns, and outcomes. Results: Compared with patients with AIS/no COVID-19, those with AIS/COVID-19 were younger, more likely to be non-Hispanic Black, Hispanic, or Asian, more likely to present with higher National Institutes of Health Stroke Scale scores, and had greater proportions of large vessel occlusions. Rates of thrombolysis and thrombectomy were similar between the groups. Door to computed tomography (median 55 [18-207] versus 35 [14-99] minutes, P<0.001), door to needle (59 [40-82] versus 46 [33-64] minutes, P<0.001), and door to endovascular therapy (114 [74-169] versus 90 [54-133] minutes, P=0.002) times were longer in the AIS/COVID-19 cohort. In adjusted models, patients with AIS/COVID-19 had decreased odds of discharge with modified Rankin Scale score of <= 2 (odds ratio, 0.65 [95% CI, 0.52-0.81], P<0.001) and increased odds of in-hospital mortality (odds ratio, 4.34 [95% CI, 3.48-5.40], P<0.001). ConclusionS: This analysis demonstrates younger age, greater stroke severity, longer times to evaluation and treatment, and worse morbidity and mortality in patients with AIS/COVID-19 compared with those with AIS/no COVID-19.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据